search
Back to results

Early Videocapsule Endoscopy for Upper Gastrointestinal Bleeding

Primary Purpose

Small Bowel Bleeding

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Videocapsule endoscopy
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Small Bowel Bleeding

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • New onset of acute gastrointestinal bleeding defined as:

    1. The presence of melena/maroon stool on physical exam OR history of melena/maroon stool within 48 hours of emergency room presentation PLUS
    2. Hemoglobin drop of ≥ 20 g/L from patient's baseline
  • Have capacity to consent
  • Hemodynamically stable (i.e. blood pressure >100/60 or pulse <110 at the time of consent)
  • Initial gastroscopy negative for active bleeding or potential bleeding source

Exclusion Criteria:

  • Inability to provide consent due to lack of capacity, language barrier or other reasons
  • Pregnant women
  • Prior history of small bowel surgery
  • Prior history of Crohn's disease
  • Prior history of small bowel or colonic strictures
  • Prior history of abdominal radiation

Sites / Locations

  • University of Alberta HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Early small bowel investigation

Colonoscopy

Arm Description

Patients in the early small bowel investigation group will undergo VCE immediately after their initial negative gastroscopy

Participants with negative gastroscopy will undergo bowel preparation and colonoscopy the next day

Outcomes

Primary Outcome Measures

Diagnostic yield
Diagnostic yield of videocapsule endoscopy after initial negative gastroscopy
Diagnostic yield of colonoscopy after initial negative gastroscopy

Secondary Outcome Measures

Time from presentation to localization of bleeding source
Recurrence of bleeding
Length of stay in hospital
Adverse events in both groups

Full Information

First Posted
October 26, 2021
Last Updated
October 31, 2022
Sponsor
University of Alberta
search

1. Study Identification

Unique Protocol Identification Number
NCT05108844
Brief Title
Early Videocapsule Endoscopy for Upper Gastrointestinal Bleeding
Official Title
A Randomized Controlled Trial Evaluating the Efficacy of Early Videocapsule Endoscopy Following Negative Gastroscopy in Patients Presenting With Suspected Upper Gastrointestinal Bleeding
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
October 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to determine whether early video capsule endoscopy (VCE) immediately after a negative gastroscopy in the setting of suspected upper gastrointestinal bleeding (UGIB) improves patient outcomes as compared to the standard approach which typically involves performing colonoscopy prior to small bowel investigations. We aim to examine the differences in diagnostic yield, total number of procedures, length of hospitalization, mortality rates, and healthcare cost between the two groups.
Detailed Description
UGIB is common medical emergency with an annual hospitalization rate of 67 cases per 100,000 and costing in excess of 1 billion dollars in the US.1 In Alberta, Canada, annual incidence of UGIB due to peptic ulcers alone is between 35.4 to 41.2 cases per 100,000 with an overall in-hospital mortality rate of 8.5%.2 The presentation of acute UGIB are variable, but most have visible signs of bleeding such as hematemesis, coffee-ground-emesis or melena.3 Clinically, these findings are used to guide management plans. For instance, a patient with suspected UGIB based on clinical presentation will typically undergo gastroscopy as the initial diagnostic test.4,5 However, it is becoming increasingly clear that clinical signs of bleeding do not always correlate with location of bleeds. Despite melena being the most common presenting symptom for UGIB, more than 10% of melena arise from the small bowel or right colon.3,4 Similarly, 15% of hematochezia, which are thought to be signs of colonic bleeding, in fact have bleeding sources in the upper GI tract.6 In essence, bleeding can be anywhere along the gastrointestinal tract regardless of patient's presentation. This poses a significant challenge for clinicians in determining which investigations to pursue in patients with suspected UGIB after a negative gastroscopy. Currently, there are no clear guidelines on this subject matter.4,5 In clinical practice, such patients often undergo colonoscopy to rule out colonic sources of bleed, before small bowel investigations with cross-sectional imaging and VCE. This is a time-consuming approach that requires multiple invasive procedures, leading to patient discomfort, prolonged hospitalization, and increased cost. The utility of colonoscopy in suspected UGIB have also been questioned by previous study that reported a diagnostic yield of less than 5%.7 Furthermore, proceeding with colonoscopy first will cause delays in small bowel investigation which may lower the detection rate of small bowel lesions.8 With these in mind, we propose the study of an alternative diagnostic approach which prioritizes small bowel investigation over colonic investigation. We propose early VCE following negative gastroscopy instead of colonoscopy. VCE is a pill shaped camera that is well tolerated, non-invasive, and offers superior mucosal imaging of the small bowel compared to cross-sectional imaging in the setting of GI bleeding.9 This approach would likely have higher diagnostic yield than the traditional approach of conducting colonoscopy first. At the present, patients with suspected UGIB and negative gastroscopy pose significant diagnostic challenges for clinicians. This study aims to help determine the importance of prioritizing small bowel investigation in this clinical setting. If this study can demonstrate the safety and efficacy of the early small bowel investigation, the results will fundamentally change the approach and management of patients with acute GI bleeding, potentially leading to better patient outcomes, reduced hospitalization, and healthcare savings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Bowel Bleeding

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Care Provider
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Early small bowel investigation
Arm Type
Experimental
Arm Description
Patients in the early small bowel investigation group will undergo VCE immediately after their initial negative gastroscopy
Arm Title
Colonoscopy
Arm Type
Active Comparator
Arm Description
Participants with negative gastroscopy will undergo bowel preparation and colonoscopy the next day
Intervention Type
Procedure
Intervention Name(s)
Videocapsule endoscopy
Intervention Description
Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
Primary Outcome Measure Information:
Title
Diagnostic yield
Description
Diagnostic yield of videocapsule endoscopy after initial negative gastroscopy
Time Frame
30 days
Title
Diagnostic yield of colonoscopy after initial negative gastroscopy
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Time from presentation to localization of bleeding source
Time Frame
30 days
Title
Recurrence of bleeding
Time Frame
30 days
Title
Length of stay in hospital
Time Frame
30 days
Title
Adverse events in both groups
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years New onset of acute gastrointestinal bleeding defined as: The presence of melena/maroon stool on physical exam OR history of melena/maroon stool within 48 hours of emergency room presentation PLUS Hemoglobin drop of ≥ 20 g/L from patient's baseline Have capacity to consent Hemodynamically stable (i.e. blood pressure >100/60 or pulse <110 at the time of consent) Initial gastroscopy negative for active bleeding or potential bleeding source Exclusion Criteria: Inability to provide consent due to lack of capacity, language barrier or other reasons Pregnant women Prior history of small bowel surgery Prior history of Crohn's disease Prior history of small bowel or colonic strictures Prior history of abdominal radiation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sergio Zepeda-Gomez, MD
Phone
780-248-1578
Email
zepedago@ualberta.ca
First Name & Middle Initial & Last Name or Official Title & Degree
David Yang, MD
Phone
647-502-7658
Email
dyyang@ualberta.ca
Facility Information:
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sergio Zepeda-Gomez
Phone
7802481578
Email
zepedago@ualberta.ca
First Name & Middle Initial & Last Name & Degree
David Yang
Phone
6475027658
Email
dyyang@ualberta.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Early Videocapsule Endoscopy for Upper Gastrointestinal Bleeding

We'll reach out to this number within 24 hrs